First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models Highlights First-in-class TRH-based compound JAK4D detects new receptor subtype in human brain. JAK4D elicits statistically significant effects in neurodegenerative animal models. JAK4D crosses the blood–brain barrier and has a clean initial toxicology profile.… Read More